Lupin, a leading pharmaceutical company, has recently welcomed two distinguished individuals, Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta, to its Board as Independent Directors. Mr. Kindler boasts an illustrious career as a healthcare executive, investor, and advisor, accumulating over…
Revolution Medicines, Inc. (Nasdaq: RVMD), a company focused on developing targeted therapies for patients with RAS-addicted cancers, has disclosed its financial results for the quarter ending March 31, 2024, alongside an update on its corporate advancements. The company’s strides in…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced its consolidated financial performance for the first quarter ended March 31, 2024, while reaffirming its full-year 2024 financial outlook. Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex, expressed satisfaction with the robust…
AstraZeneca has confirmed the successful conclusion of its equity investment agreement with Cellectis, a clinical-stage biotech firm. The investment, along with a research collaboration deal unveiled in November 2023, aims to harness Cellectis’ proprietary gene editing technologies and manufacturing capabilities…
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological Association Meeting 2024 in San Antonio, TX. This analysis focused…
Moderna, Inc. (NASDAQ: MRNA) has released its financial results for the first quarter of 2024, along with key updates on its business operations. Stéphane Bancel, the Chief Executive Officer of Moderna, emphasized the company’s strategic approach amidst the impending launches…
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) have received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv), granting full approval for its use in treating patients…
AstraZeneca’s Truqap (capivasertib) combined with Faslodex (fulvestrant) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced or metastatic breast cancer that is estrogen receptor (ER)-positive and HER2-negative. This recommendation comes…
Eli Lilly and Company (NYSE: LLY) unveiled its financial performance for the first quarter of 2024 today. David A. Ricks, Lilly’s chair and CEO, commented on the company’s robust year-over-year revenue growth, attributing it to strong sales of Mounjaro and…
Alentis Therapeutics, a cutting-edge biotech firm dedicated to combatting organ fibrosis and Claudin-1 positive tumors, has just announced the appointment of Dr. Alberto Toso as its Chief Scientific Officer, effective immediately. Dr. Toso’s transition into this role marks a significant…
Eli Lilly and Company (NYSE: LLY) has received notification of an unsolicited “mini-tender” offer from Tutanota LLC (“Tutanota”), proposing to acquire up to 62,500 shares of Lilly common stock, which represents significantly less than one percent of Lilly’s outstanding common…
Merck, a prominent science and technology company, convened its 29th Annual General Meeting virtually today. With a significant majority, shareholders approved all items on the agenda, including the proposed dividend of €2.20 per share. Furthermore, the meeting saw the election…
